Eli Lilly to Present New Data on Imlunestrant, Olomorasib, LY4170156, and Verzenio® at 2025 ASCO Annual Meeting
Eli Lilly and Company (NYSE: LLY) announced today that new clinical data from its oncology pipeline—including imlunestrant, olomorasib, LY4170156, and Verzenio® (abemaciclib)—will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 through June 3 in Chicago.
Presentation Highlights
Imlunestrant (Oral Selective Estrogen Receptor Degrader, SERD)
Two presentations will highlight data from the Phase 3 EMBER-3 trial in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC):
- Oral Presentation: Patient-reported outcomes (PROs) comparing imlunestrant, standard endocrine therapy, and imlunestrant combined with abemaciclib.
- Abstract #1001
- Date/Time: Saturday, May 31, 1:15–4:15 p.m. CDT
- Location: Hall B1 | Live Stream
- Presenter: Dr. Giuseppe Curigliano
- Poster Presentation: Expanded safety analysis of imlunestrant with or without abemaciclib.
- Abstract #1060
- Date/Time: Monday, June 2, 9 a.m.–12 p.m. CDT
- Location: Hall A – Posters and Exhibits | On Demand
- Presenter: Dr. Joyce O’Shaughnessy
Olomorasib (KRAS G12C Inhibitor)
Updated results from the ongoing Phase 1/2 study of olomorasib, a potent second-generation KRAS G12C inhibitor with early signs of CNS activity, will be presented in two oral sessions:
- Combination with Cetuximab in Colorectal Cancer (CRC)
- Abstract #3507
- Date/Time: Friday, May 30, 2:45–5:45 p.m. CDT
- Location: Arie Crown Theater | Live Stream
- Presenter: Dr. Antoine Hollebecque
- Combination with Pembrolizumab in Non-Small Cell Lung Cancer (NSCLC)
- Abstract #8519
- Date/Time: Monday, June 2, 8–9:40 a.m. CDT
- Location: Arie Crown Theater | Live Stream
- Presenter: Dr. Alexander I. Spira
LY4170156 (Antibody-Drug Conjugate Targeting FRα)
Early findings from the first-in-human Phase 1a/1b trial of LY4170156 in patients with platinum-resistant ovarian cancer will be presented as a poster:
- Abstract #3023
- Date/Time: Monday, June 2, 1:30–4:30 p.m. CDT
- Location: Hall A – Posters and Exhibits | On Demand
- Presenter: Dr. Isabelle Ray-Coquard
LY4170156 is a novel ADC consisting of a humanized, Fc-silent monoclonal antibody targeting folate receptor alpha (FRα), linked to the topoisomerase I inhibitor exatecan through a proprietary cleavable polysarcosine linker.
Verzenio® (Abemaciclib)
Lilly will also present an analysis on the effect of body mass index (BMI) on the efficacy and safety of abemaciclib in breast cancer patients enrolled in the monarchE trial:
- Abstract #520
- Date/Time: Monday, June 2, 9 a.m.–12 p.m. CDT
- Location: Hall A – Posters and Exhibits | On Demand
- Presenter: Dr. Christine Desmedt
These presentations underscore Lilly’s continued commitment to advancing innovative cancer therapies through robust clinical research.
About Imlunestrant
Imlunestrant is an investigational, brain-penetrant, oral selective estrogen receptor degrader (SERD), that delivers continuous ER inhibition, including in ESR1-mutant cancers. The estrogen receptor (ER) is the key therapeutic target for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Novel degraders of ER may overcome endocrine therapy resistance while providing consistent oral pharmacology and convenience of administration. Imlunestrant is currently being studied as a treatment for advanced breast cancer and as an adjuvant treatment in early breast cancer, including: NCT04975308, NCT05514054, NCT04188548, NCT05307705.
About Olomorasib
Olomorasib (LY3537982) is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. KRAS is the most common oncogene across all tumor types, and KRAS G12C mutations occur in 13% of patients with non-small cell lung cancer (NSCLC), and 1-3% of patients with other solid tumors.1 Olomorasib is a highly potent covalent inhibitor with potential for greater than 90% target occupancy, which may allow for safer combinations with less toxicity.2
